Abstract
WITH A FEW EXCEPTIONS, earnings for pharmaceutical firms did not live up to investors' and each company's own expectations, both in the fourth quarter and for the full year. In addition to well-pub...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have